The unfortunate trend of major blood pressure medication recalls is continuing into 2019 with Aurobindo Pharma USA, Inc. recently recalling 80 lots of valsartan tablets due to the possibility of a cancerous impurity. Though it is a precautionary measure, it has serious impacts on both the consumers and the companies. Robert Handfield, a professor of supply chain management at NC State, commented on the manufacturing side of the recall and how the affected drugs were traced back to factories in India and China. “Impurities were introduced through chemical reactions and so forth,” said Handfield discussing factors such as poor training that affected the recall. Read more about the recall on MSN.